Clinical Trial Update: Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Trastuzumab Rezetecan followed by CDK4/6 inhibitors and endocrine therapy for HR+/HER2-low/ultra-low advanced breast cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitors
• Endocrine therapy
• Trastuzumab Rezetecan

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Advanced Breast Cancer | Phase 2 | Status: RECRUITING